BioCentury | Aug 17, 2017
Finance

Built to purpose

...NA (A) Infectious Single target 2013 2016 Returned rights to sole product to Mymetics Corp. (OTCQB:MYMX...
...NYSE:MRK), Kenilworth, N.J. Mitobridge Inc., Cambridge, Mass. MPM Capital, South San Francisco, Calif. Mymetics Corp. (OTCQB:MYMX...
BioCentury | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

...of Medicine Distillery Therapeutics Musculoskeletal Musculoskeletal Myomixer myoblast fusion factor (MINION; MYMX) Mouse studies identified MINION...
BioCentury | Jul 20, 2017
Translation in Brief

Minion power

...a team co-led by Srihari Sampath and Srinath Sampath identified myomixer myoblast fusion factor (MINION; MYMX...
...to muscle fibers. Fusion of the muscle cells depended on both MINION and MYMK; although MINION-deficient...
...search for diseases associated with MINION deficiency, but little is known about the role of MINION...
BioCentury | Feb 29, 2016
Company News

Illumina, Oxford Nanopore genomics news

...MinION and PromethION devices infringe patents to which Illumina has exclusive rights. Illumina alleged that MinION...
...the U.S. District Court for the Southern District of California. Oxford Nanopore sells the hand-held MinION...
...an early access program for its PromethION sequencer. PromethION is a larger benchtop version of MinION...
BioCentury | Feb 25, 2016
Company News

Illumina suing Oxford Nanopore

...lawsuits against nanopore-based sequencing company Oxford Nanopore Technologies Ltd. (Oxford, U.K.) alleging that Oxford Nanopore's MinION...
...and PromethION devices infringe patents to which Illumina has exclusive rights. Illumina is alleging that MinION...
...the U.S. District Court for the Southern District of California. Oxford Nanopore sells the hand-held MinION...
BioCentury | Jul 27, 2015
Finance

From pore to rich

...share classes. Oxford Nanopore has the most advanced nanopore-based sequencing platform and sells its hand-held MinION...
...an early access program for its PromethION sequencer, which is a larger benchtop version of MinION...
BioCentury | Mar 19, 2015
Product R&D

AAV for HIV

...Pharmaceuticals Inc. Pennvax-GP DNA vaccine targeting HIV clades A, C and D Preclin Mymetics Corp. (OTCBB:MYMX...
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

...an influenza vaccine Mercia Pharma Inc. Preclinical P3CSK4 TLR2 lipopeptide ligand RSV vaccine Mymetics Corp. (OTCBB:MYMX...
BioCentury | Aug 13, 2014
Financial News

Oxford Nanopore raises $58M

...round include The CF Woodford Equity Income Fund. The biotech has begun rolling out its MinION...
BioCentury | May 26, 2014
Finance

Europe's Iceberg 2014: Premier League teams

...biotech has the most advanced nanopore-based sequencing platform and has begun to roll out its MinION...
...Development Corp. Oxford Nanopore Technologies Ltd. Nanopore-based sequencing platform including the GridION system and miniaturized MinION...
Items per page:
1 - 10 of 51